Results 51 to 60 of about 124,419 (219)
MicroRNA-98 Inhibits Hepatic Stellate Cell Activation and Attenuates Liver Fibrosis by Regulating HLF Expression
Frontiers in Cell and Developmental Biology, 2020 Liver fibrosis is a major endpoint of patients with chronic liver diseases. The molecular mechanisms behind liver fibrosis remain largely unknown. Many studies have indicated the role of microRNA (miRNA) in hepatic tumorigenesis. But the role of miRNA in Qi Wang, Qi Wang, Qi Wang, Qi Wang, Qi Wang, Song Wei, Song Wei, Song Wei, Song Wei, Song Wei, Haoming Zhou, Haoming Zhou, Haoming Zhou, Haoming Zhou, Lei Li, Lei Li, Lei Li, Lei Li, Shun Zhou, Shun Zhou, Shun Zhou, Shun Zhou, Chengyu Shi, Chengyu Shi, Chengyu Shi, Chengyu Shi, Yong Shi, Yong Shi, Yong Shi, Yong Shi, Jiannan Qiu, Jiannan Qiu, Jiannan Qiu, Jiannan Qiu, Ling Lu, Ling Lu, Ling Lu, Ling Lu, Ling Lu, Ling Lu, Ling Lu +40 moredoaj +1 more sourceGemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors
Pediatric Blood &Cancer, EarlyView.ABSTRACT
Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...Maria Frost, Olayinka Okeleji, Amr Elgehiny, Douglas Harrison, Cynthia Herzog, Jeremy Connors, Demetrios Petropoulos, Priti Tewari, Dristhi Ragoonanan, Yago Nieto, Irtiza N. Sheikh +10 morewiley +1 more sourceEndoscopic treatment of biliary complications in donors after living donor liver transplantation in a high volume transplant center
The Turkish Journal of Gastroenterology, 2020 Background/Aims: Although living donor liver transplantation (LDLT) has been accepted as a primary treatment for adults with end-stage liver disease, concerns about donor health have been emerged.Mehmet Ali Erdoğan, Yasir Furkan Çağın, Yahya Atayan, Yılmaz Bilgiç, Oğuzhan Yıldırım, Ali Riza Çalışkan, Murat Aladağ, Melih Karıncaoğlu, Sezai Yılmaz, Muhsin Murat Harputluoğlu +9 moredoaj +1 more sourceCPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background/Objectives
Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.Jonathan D. Bender, Lauren Pommert, Lori R. Backus, Andrea Bidwell, Courtney Blank, Erin H. Breese, Karen C. Burns, Adam Lane, Lynn H. Lee, Benjamin Mizukawa, Robin E. Norris, Maureen M. O'Brien, Daniel Peck, Christine Phillips, Thomas D. Ryan, Jennifer Young, Michael Absalon, John P. Perentesis +17 morewiley +1 more sourceNovel Genetic Risk Factor Identified for L‐Asparaginase‐Induced Pancreatitis in Pediatric Patients With Cancer
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background
L‐asparaginase is a critical component in treatment protocols for pediatric acute lymphoblastic leukemia. Acute pancreatitis reactions can necessitate delays and, in some cases, discontinuation of L‐asparaginase, which compromises outcomes.Edward J. Raack, Wan‐Chun Chang, Miguel Cordova‐Delgado, Spencer J. Anderson, Jessica N. Trueman, Erika N. Scott, Catrina M. Loucks, Shahrad R. Rassekh, Gabriella S. S. Groeneweg, Michelle Higginson, Kathy Li, Fudan Miao, Derek Yau, Donna Johnston, Mounira Ibrahim, Maja Krajinovic, Thai Hoa Tran, Jessica Tewfik, Jean‐François Bussières, Thaïna‐Rafi Jean‐Baptiste, Denis Lebel, Lucie Pecheux, Bina Gyawali, Gregory Guilcher, Gesche Riabowol, Geert ’t Jong, Michelle Staub, Geoff Cuvelier, Kathleen Felton, Sara Khalaj, Michael Rieder, Awatif Abuzgaia, Tamorah Lewis, Himal Ghimire, Paul Nathan, Kerry Goralski, Ketan Kulkarni, Zara Forbrigger, Colin J. D. Ross, Bruce C. Carleton +39 morewiley +1 more sourceOutcomes and Surgical Management of Malignant Rhabdoid Tumor of the Kidney: A Report From the Pediatric Surgical Oncology Research Collaborative
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose
Malignant rhabdoid tumor of the kidney (MRTK) is a rare, aggressive tumor seen in young children. The optimal timing of resection for locally advanced tumors is not well‐defined. The purpose of this study is to evaluate modern oncologic outcomes and the impact of surgical timing. Methods
A multicenter retrospective review was performed Hannah N. Rinehardt, Elisabeth T. Tracy, Anghela Paredes, Catherine Beckhorn, Harold J. Leraas, Joseph Fusco, Katlyn G. McKay, Nelly‐Ange T. Kontchou, Zachary J. Kastenberg, David W. Hoyt, Jonathan Roach, Emily K. Myers, Nicholas G. Cost, Bhargava Mullapudi, Charles R. Marchese, Amanda R. Jensen, Timothy B. Lautz, Michela Carter, Roshni Dasgupta, John Lundstedt, Joseph G. Brungardt, Lindsay Talbot, Andrew M. Davidoff, Andrew J. Murphy, Jennifer H. Aldrink, Sara Mansfield, Nelson Piche, Annie Le‐Nguyen, Dave R. Lal, Brian T. Craig, Jennifer M. Schuh, Barrett P. Cromeens, Sindhu Mannava, Shannon Castle, Adriana Lopez, Kelsey Mello, Joshua Short, Robin T. Petroze, Shay Rajaval, Grace R. Thompson, Peter Mattei, David H. Rothstein, Elizabeth Fialkowski, Kathryn Fowler, Nathan Martchenke, Barrie S. Rich, Richard D. Glick, Erin G. Brown, Kathleen Doyle, Paige Abril, Natashia Seemann, Jacob Davidson, Claire A. Wilson, Hau D. Le, Devashish Joshi, Michael Stellon, Tamer Ahmed, Alexandra Dimmer, Peter F. Ehrlich, Maya Hammoud, Keyonna Williams, Christa N. Grant, Merit Gorgy, Stephanie F. Polites, Julia Debertin, Danielle B. Cameron, Alyssa Stetson, Eugene S. Kim, William G. Lee, Aaron Barkhordar, Mary Austin, Brian A. Coakley, Anastasia Kahan, Joseph T. Murphy, Michael Pitonak, Chloé Boehmer, Marcus M. Malek +76 morewiley +1 more sourcePhosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma
Cell Death and DiseaseHepatocellular carcinoma (HCC) is a highly heterogeneous and malignant cancer with poor overall survival. The application of sorafenib is a major breakthrough in the treatment of HCC.Yiwei Liu, Ke Shao, Wendong Yang, Qi Shen, Mengru Lu, Zhiying Shao, Sufang Chu, Yuming Wang, Xuehao Wang, Xiaofeng Chen, Jin Bai, Xiaofeng Wu +11 moredoaj +1 more sourceAdjunctive Therapeutic Plasma Exchange in Refractory Adult‐Onset Still's Disease Complicated by Secondary Macrophage Activation Syndrome: A Single‐Center Experience
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Introduction
Adult‐onset Still's disease (AOSD) complicated by macrophage activation syndrome (MAS) carries substantial mortality. The role of therapeutic plasma exchange (TPE) remains uncertain. Methods
We retrospectively analyzed patients with AOSD‐MAS treated with TPE at a single‐center.Masataka Ueda, Tomohiro Saito, Masahide Mizobuchi, Tomoki Shimomura, Saki Kawamori, Mitsuru Kawanishi, Natsuko Hattori, Jo Sugiyama, Satoshi Tsubata, Hanami Horiguchi, Kazuki Abe, Nao Iida, Yuki Kajio, Nao Oguro, Ryo Yanai, Hirokazu Honda +15 morewiley +1 more source